BioScrip Inc (NASDAQ:BIOS)’s share price traded up 10.5% during trading on Monday . The company traded as high as $2.12 and last traded at $2.10. 3,081,050 shares traded hands during mid-day trading, an increase of 151% from the average session volume of 1,226,480 shares. The stock had previously closed at $1.90.
A number of equities analysts recently commented on the company. BidaskClub downgraded BioScrip from a “buy” rating to a “hold” rating in a report on Thursday, January 17th. Canaccord Genuity decreased their target price on BioScrip from $5.00 to $3.50 and set a “buy” rating for the company in a research report on Monday, March 18th. Zacks Investment Research cut BioScrip from a “hold” rating to a “sell” rating in a research report on Thursday, January 3rd. TheStreet raised BioScrip from a “d+” rating to a “c-” rating in a research report on Monday, November 26th. Finally, Stephens cut BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 target price for the company. in a research report on Monday, March 18th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $4.70.
The stock has a market capitalization of $243.49 million, a PE ratio of -4.29 and a beta of 0.76.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC boosted its position in shares of BioScrip by 13.7% in the fourth quarter. Squarepoint Ops LLC now owns 52,389 shares of the company’s stock valued at $187,000 after acquiring an additional 6,303 shares during the period. Virtu Financial LLC boosted its position in shares of BioScrip by 60.6% in the fourth quarter. Virtu Financial LLC now owns 18,208 shares of the company’s stock valued at $65,000 after acquiring an additional 6,868 shares during the period. Maven Securities LTD bought a new stake in shares of BioScrip in the fourth quarter valued at approximately $45,000. Caxton Associates LP bought a new stake in shares of BioScrip in the fourth quarter valued at approximately $52,000. Finally, Royce & Associates LP boosted its position in shares of BioScrip by 1.1% in the fourth quarter. Royce & Associates LP now owns 2,228,500 shares of the company’s stock valued at $7,956,000 after acquiring an additional 24,500 shares during the period. 82.51% of the stock is owned by institutional investors.
BioScrip Company Profile (NASDAQ:BIOS)
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Featured Story: Fiduciary
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.